These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6390834)

  • 1. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection.
    Thistlethwaite JR; Cosimi AB; Delmonico FL; Rubin RH; Talkoff-Rubin N; Nelson PW; Fang L; Russell PS
    Transplantation; 1984 Dec; 38(6):695-701. PubMed ID: 6390834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OKT3 treatment of steroid-resistant renal allograft rejection.
    Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
    Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
    Cosimi AB; Burton RC; Colvin RB; Goldstein G; Delmonico FL; LaQuaglia MP; Tolkoff-Rubin N; Rubin RH; Herrin JT; Russell PS
    Transplantation; 1981 Dec; 32(6):535-9. PubMed ID: 7041358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
    Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
    Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients.
    Leone MR; Barry JM; Alexander SR; Melvin T; Striegel J; Reller K; Henell KR; Kimball J; Funnell MB; Goldstein G
    J Pediatr; 1990 May; 116(5):S86-91. PubMed ID: 2139465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection.
    Norman DJ; Shield CF; Barry JM; Henell K; Funnell MB; Lemon J
    Nephron; 1987; 46 Suppl 1():41-7. PubMed ID: 3306424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
    Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection.
    Norman DJ; Shield CF; Barry J; Bennett WM; Henell K; Kimball J; Funnell B; Hubert B
    Am J Kidney Dis; 1988 Feb; 11(2):107-10. PubMed ID: 3277400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring immunosuppression following renal transplantation.
    Giorgi JV; Cosimi AB; Colvin RB; Goldstein G; Delmonico FL; Russell PS
    Diagn Immunol; 1983; 1(3):174-8. PubMed ID: 6388969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function.
    Benvenisty AI; Cohen D; Stegall MD; Hardy MA
    Transplantation; 1990 Feb; 49(2):321-7. PubMed ID: 2137654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.
    D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Maki DG; Belzer FO
    Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OKT3: First-dose safety and success.
    Cosimi AB
    Nephron; 1987; 46 Suppl 1():12-8. PubMed ID: 3306421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
    Chatenoud L; Bach JF
    Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3 rescue therapy in pancreas-allograft rejection.
    Stratta RJ; Sollinger HW; D'Alessandro AM; Pirsch JD; Kalayoglu M; Belzer FO
    Diabetes; 1989 Jan; 38 Suppl 1():74-8. PubMed ID: 2521330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection.
    Deierhoi MH; Barber WH; Curtis JJ; Julian BA; Luke RG; Hudson S; Barger BO; Diethelm AG
    Am J Kidney Dis; 1988 Feb; 11(2):86-9. PubMed ID: 3277412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte function in patients treated with monoclonal anti-T3 antibody for acute cadaveric renal allograft rejection.
    Bowen A; Edwards LC; Gailiunas P; Helderman JH
    Transplantation; 1984 Nov; 38(5):489-93. PubMed ID: 6388070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
    Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.
    Vigeral P; Chkoff N; Chatenoud L; Campos H; Lacombe M; Droz D; Goldstein G; Bach JF; Kreis H
    Transplantation; 1986 Jun; 41(6):730-3. PubMed ID: 3520988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.
    Ortho Multicenter Transplant Study Group
    N Engl J Med; 1985 Aug; 313(6):337-42. PubMed ID: 2861567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.